Status:
COMPLETED
An Open-Label Trial of Pregabalin in Patients With Fibromyalgia
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Fibromyalgia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia Study A0081056 and who wish to receive open-label pregabal...
Eligibility Criteria
Inclusion
- Patients must have met the inclusion criteria for the preceding fibromyalgia Protocol A0081056
- Must have received pregabalin/placebo under double-blind conditions.
Exclusion
- Patients may not participate in the study if they experienced a serious adverse event during the previous fibromyalgia Study A0081056 which was determined to be related to the study medication by the investigator or the sponsor.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
428 Patients enrolled
Trial Details
Trial ID
NCT00151528
Start Date
January 1 2005
End Date
June 1 2006
Last Update
January 22 2021
Active Locations (93)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294-3405
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294-6909
3
Pfizer Investigational Site
Huntsville, Alabama, United States, 35801
4
Pfizer Investigational Site
Phoenix, Arizona, United States, 85023